 This is a double-blind, randomized, placebo-controlled, multi-cohort Phase 11b study in patients that are currently being treated for chronic HBV infection. For all cohorts, patients must be receiving antiviral treatment with either tenofovir disoproxil fumarate TDF or entecavir ENT for at least two years, and have their HBV infection well-controlled 